Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Trinity Biotech (TRIB) Goodwill & Intangibles (2016 - 2025)

Historic Goodwill & Intangibles for Trinity Biotech (TRIB) over the last 17 years, with Q2 2025 value amounting to $55.9 million.

  • Trinity Biotech's Goodwill & Intangibles rose 3382.23% to $55.9 million in Q2 2025 from the same period last year, while for Jun 2025 it was $55.9 million, marking a year-over-year increase of 3382.23%. This contributed to the annual value of $51.3 million for FY2024, which is 21556.85% up from last year.
  • Per Trinity Biotech's latest filing, its Goodwill & Intangibles stood at $55.9 million for Q2 2025, which was up 3382.23% from $51.3 million recorded in Q4 2024.
  • Over the past 5 years, Trinity Biotech's Goodwill & Intangibles peaked at $55.9 million during Q2 2025, and registered a low of $15.8 million during Q2 2023.
  • Its 5-year average for Goodwill & Intangibles is $34.7 million, with a median of $36.0 million in 2021.
  • As far as peak fluctuations go, Trinity Biotech's Goodwill & Intangibles tumbled by 5933.2% in 2023, and later surged by 21556.85% in 2024.
  • Over the past 5 years, Trinity Biotech's Goodwill & Intangibles (Quarter) stood at $36.0 million in 2021, then fell by 1.98% to $35.3 million in 2022, then plummeted by 53.87% to $16.3 million in 2023, then soared by 215.57% to $51.3 million in 2024, then grew by 8.91% to $55.9 million in 2025.
  • Its last three reported values are $55.9 million in Q2 2025, $51.3 million for Q4 2024, and $46.7 million during Q3 2024.